Rexahn Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,998,991, entitled “Neurotherapeutic treatment for sexual dysfunction.”

The patent covers a method for treating erectile dysfunction and premature ejaculation in males, as well as enhancing libido in females. Rick Soni, president of Rexahn, said, “We are very pleased to obtain this new US patent coverage for the neurotherapeutic treatment of sexual dysfunction, especially as we make progress in the development of Zoraxel, currently in phase II trials for erectile dysfunction.”

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs.